ZAMBON UK LIMITED

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

• Turnover

  -41.2%

  £7,093,000 → £4,172,000

• Cash

  +1.4%

  £3,230,000 → £3,276,000

• Net assets

  -0.7%

  £4,191,000 → £4,161,000

• Employees

  -30%

  10 → 7

• Operating profit

  -9%

  £611,000 → £556,000

• Profit before tax

  -10.2%

  £734,000 → £659,000

• Wages

  -34.1%

  £1,110,000 → £732,000

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

1. ZAMBON UK LIMITED 2022-02-01 → present
2. PROFILE PHARMA LIMITED 2001-12-31 → 2022-02-01
3. PT PHARMA LIMITED 2000-12-21 → 2001-12-31
4. PRODOSE PHARMA LIMITED 2000-07-19 → 2000-12-21
5. BONDCO 806 LIMITED 2000-05-31 → 2000-07-19

Accounting basis

FRS 101 'Reduced Disclosure Framework'

Reporting scope

Standalone (parent only)

Auditor

Moore (South) LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“The Directors have a reasonable expectation that the Company has adequate resources to continue in operational existence for the foreseeable future. Thus, they continue to adopt the going concern basis in preparing the annual report and accounts.”

Significant events

• “The supply and revenue of Zambon UK's inhaled antibiotic for the treatment of Cystic Fibrosis ended in 2025 due to the withdrawal of the nebulizer by the 3rd party manufacturer that has been used to deliver the drug.”
• “On 25th February 2026 the Directors elected to pay a global amount of dividend of £491k.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

2

last 12 months

Capital events

0

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.